Malawi: Poor Sanitation Accounts for 52 Percent of the Total Disease Burden in Malawi
[Nyasa Times] Poor sanitation accounts for 52 percent of the total disease burden in Malawi, with diarrhoea alone accounting for seven per cent of under-five deaths, latest statistics have shown. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2022 Category: African Health Source Type: news
Vitamin D overdose warning: How you can actually take too much of something so good
The middle-aged patient, from Kent, lost two stone in three months after suffering from constant vomiting, diarrhoea and stomach pains. He had been taking a cocktail of supplements. (Source: the Mail online | Health)
Source: the Mail online | Health - July 7, 2022 Category: Consumer Health News Source Type: news
You can overdose on vitamin D
The middle-aged patient, from Kent, lost two stone in three months after suffering from constant vomiting, diarrhoea and stomach pains. He had been taking a cocktail of supplements. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2022 Category: Consumer Health News Source Type: news
New shipment of WHO health supplies for Afghanistan earthquake response delivered to Kabul from ...
28 June 2022 – A flight containing 25 metric tonnes of WHO health supplies has just landed in Kabul from WHO’s logistics hub in Dubai to support the Afghanistan earthquake response.
The shipment includes enough essential medicines, trauma and surgical supplies, and other critical health supplies for almost 400 000 people in need of health care services, including 1500 trauma patients and 2750 suspected cases of acute watery diarrhoea.
“WHO is grateful for the continued support of His Highness Sheikh Mohammed bin Rashid Al Maktoum, the Vice President and Prime Minister of the United Arab Emirates, and Ruler of Dubai...
Source: WHO EMRO News - June 28, 2022 Category: Middle East Health Source Type: news
Viruses survive in fresh water by ‘hitchhiking’ on plastic, study finds
Intestinal viruses such as rotavirus were found to be infectious for up to three days by attaching to microplastics, research showsDangerous viruses can remain infectious for up to three days in fresh water by hitchhiking on plastic, researchers have found.Enteric viruses that cause diarrhoea and stomach upsets, such as rotavirus, were found to survive in water by attaching to microplastics, tiny particles less than 5mm long. They remain infectious, University of Stirling researchers found, posing a potential health risk.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 27, 2022 Category: Science Authors: Karen McVeigh Tags: Plastics Environment Health Oceans Pollution Society Biology Science Microbiology Source Type: news
Janssen Receives Positive CHMP Opinion for IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, June 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a new treatment option with IMBRUVICA® (ibrutinib) in an oral fixed-duration combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). Outcomes for patients with CLL have improved in the last decade with the advent of oral therapies that target the underlying disease biology.[1] This provides the opportunity...
Source: Johnson and Johnson - June 24, 2022 Category: Pharmaceuticals Source Type: news
European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, BELGIUM, 26 May 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license a...
Source: Johnson and Johnson - May 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, where Polivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression ¹Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today anno...
Source: Roche Investor Update - May 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, where Polivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression ¹Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today anno...
Source: Roche Media News - May 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, wherePolivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment withPolivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression1Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announce...
Source: Roche Investor Update - May 25, 2022 Category: Pharmaceuticals Source Type: news
Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics
Clostridioides difficile is a Gram-positive anaerobe that can cause a spectrum of disorders that range in severity from mild diarrhoea to fulminant colitis and/or death. The bacterium produces up to three toxins, which are considered the major virulence factors in C. difficile infection. These toxins promote inflammation, tissue damage and diarrhoea. In this Review, we highlight recent biochemical and structural advances in our understanding of the mechanisms that govern host-toxin interactions. Understanding how C. difficile toxins affect the host forms a foundation for developing novel strategies for treatment and preven...
Source: Current Awareness Service for Health (CASH) - May 20, 2022 Category: Consumer Health News Source Type: news
NHS doctors to stop issuing prescriptions for 35 minor medical conditions - what are they?
THE NHS has announced plans to scrap prescriptions for 35 conditions in a bid to save the money it spends on drugs available over-the-counter . The body said it will no longer issue treatments for a range of minor conditions, such as diarrhoea, oral thrush and ailments associated with pain. (Source: Daily Express - Health)
Source: Daily Express - Health - May 19, 2022 Category: Consumer Health News Source Type: news
Hepatitis in children: How many cases are there?
It looks likely that a common virus which usually causes colds, vomiting and diarrhoea has a role to play. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 4, 2022 Category: Consumer Health News Source Type: news
New three-year data for Roche ’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
91% of infants treated withEvrysdi in the FIREFISH study were still alive at three yearsInfants treated withEvrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 secondsEvrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to dateBasel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi ® (risdiplam) in infants with symptomatic Type 1 spinal mu...
Source: Roche Media News - April 29, 2022 Category: Pharmaceuticals Source Type: news
New three-year data for Roche ’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
91% of infants treated withEvrysdi in the FIREFISH study were still alive at three yearsInfants treated withEvrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 secondsEvrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to dateBasel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi ® (risdiplam) in infants with symptomatic Type 1 spinal mu...
Source: Roche Investor Update - April 29, 2022 Category: Pharmaceuticals Source Type: news
